Matrix Asset Advisors Inc. NY Acquires 21,459 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Matrix Asset Advisors Inc. NY boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 26.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,172 shares of the medical equipment provider's stock after acquiring an additional 21,459 shares during the period. Zimmer Biomet makes up approximately 1.6% of Matrix Asset Advisors Inc. NY's holdings, making the stock its 27th largest holding. Matrix Asset Advisors Inc. NY's holdings in Zimmer Biomet were worth $12,434,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clear Street Markets LLC bought a new position in Zimmer Biomet during the fourth quarter valued at about $27,000. Dark Forest Capital Management LP bought a new position in Zimmer Biomet during the first quarter valued at about $35,000. Lazard Asset Management LLC increased its stake in Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 117 shares during the period. Activest Wealth Management increased its stake in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 275 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in shares of Zimmer Biomet by 67.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 351 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 141 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Evercore ISI upped their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Thursday. Canaccord Genuity Group reissued a "hold" rating and issued a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Barclays boosted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock an "underweight" rating in a report on Monday, February 12th. JPMorgan Chase & Co. boosted their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a report on Friday, February 9th. Finally, Truist Financial boosted their target price on Zimmer Biomet from $133.00 to $135.00 and gave the stock a "hold" rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and an average target price of $139.39.

Zimmer Biomet Trading Down 0.2 %

Shares of NYSE:ZBH traded down $0.22 during midday trading on Friday, hitting $127.34. The company had a trading volume of 791,725 shares, compared to its average volume of 1,520,502. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The stock has a market cap of $26.16 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 2.39 and a beta of 1.01. The firm has a fifty day simple moving average of $126.39 and a 200 day simple moving average of $118.51.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm's revenue was up 6.3% on a year-over-year basis. During the same period last year, the company earned $1.88 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet's payout ratio is presently 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.